Cognition Therapeutics Inc (CGTX) company profile
Close on Nov 17, 2026Market cap $59.90MP/E –Yield –
About Cognition Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Cognition is a clinical-stage biopharmaceutical company that discovers and develops small molecule drug candidates for age-related degenerative disorders of the central nervous system and retina. The company focuses on developing disease-modifying therapies designed to protect neuronal synapses from toxic protein oligomers. Its primary pipeline candidate is zervimesine, also identified as CT1812, an orally administered therapeutic being evaluated for Alzheimer’s disease and dementia with Lewy bodies. Its target recipients are patients experiencing cognitive decline, mild cognitive impairment, and associated neurodegenerative conditions.
In terms of clinical scale, more than 780 participants have received zervimesine across various clinical trials. The company conducts its ongoing Phase 2 START study across 45 clinical trial sites in collaboration with a specialized research consortium. Its regulatory engagements span agencies in the United States and Europe, including interactions with the United States Food and Drug Administration and guidance from the European Medicines Agency. The provided text does not state the location of the company's headquarters.
Summary of the business section of Cognition Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cognition Therapeutics Inc
- Founded
- 2007
- Headquarters
- Purchase, NY
- Address
- 2500 Westchester Ave 10577
- Phone
- (412) 481-2210
- Website
- www.cogrx.com
- Employees
- 14, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Philadelphia, PA
Stock & identifiers
- Ticker
- CGTX
- Exchange
- Nasdaq
- IPO date
- Oct 12, 2021
- Shares outstanding
- 95M, Aug 4, 2026
- Public float
- $18.16M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1455365
- CUSIP
- 19243B102
- ISIN
- US19243B1026
- FIGI
- BBG001J2P8S7
- Share class FIGI
- BBG001V0GFB9
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lisa Ricciardi | CEO & President, Director | 1,754,702 |
| John Brendan Doyle | Chief Financial Officer | 618,942 |
| Anthony Caggiano | Chief Medical Officer | 874,906 |
| Aaron G.L. Fletcher | Director | 6,056,229 |
| Bios Equity Partners, LP | Director | – |
| Ellen B. Richstone | Director | 83,500 |
| Brett P. Monia | Director | 73,500 |
| BIOS Fund I, LP | Director | 5,505,905 |
| Bios Equity Partners II, LP | Director | 6,014,500 |
| BIOS Capital Management, LP | Director | – |
| BIOS Fund II, LP | Director | – |
| BIOS Fund I QP, LP | Director | 5,499,905 |
| Jack A. Khattar | Director | 73,500 |
| BIOS Advisors GP, LLC | Director | 6,048,500 |
| BIOS Fund II QP, LP | Director | – |
| Peggy Wallace | Director | 111,461 |
| BIOS Memory SPV I, LP | Director | 6,081,229 |
| BP Directors, LP | Director | – |
| BIOS Equity Partners III, LP | Director | – |
| BIOS Fund III, LP | Director | 6,048,500 |
| BIOS Fund III QP, LP | Director | 5,499,905 |
| BIOS Fund III NT, LP | Director | 5,483,841 |
| BIOS Memory SPV II, LP | Director | 5,505,905 |
| Leslie W. Kreis | Director | 6,014,500 |
| Cavu Advisors, LLC | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Lisa Ricciardi President and Chief Executive Officer | $651.02K | $396.46K | $393.86K | $18.30K | $1.46M | -4% |
| Anthony Caggiano, M.D., Ph.D. Chief Medical Officer | $503.01K | $185.26K | $221.32K | $18.30K | $927.89K | -19% |
| John Doyle Chief Financial Officer | $460.58K | $185.26K | $202.65K | $18.30K | $866.79K | +7% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 12, 2021
- Offer price
- $12.00
- Securities offered
- 3,768,116
- Gross proceeds
- $45.22M
- Exchange
- Nasdaq
- First trading day
- Oct 11, 2021
- First-day close
- $12.30+2.5%
- Lock-up ends (est.)
- Apr 9, 2022
“The initial public offering price per share is $12.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 1, 2026, we had 14 employees, 14 of whom were full-time and 8 of whom were engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 5, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 13, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 12, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 6, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 28, 2010 | Name change | Name changed from COGNITION THERAPUTICS INC to Cognition Therapeutics Inc |
See a number that looks wrong?